A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
||Male and Female Patients
|U.S. Govt. ID:
||Reaundra McCullough-Roach: 212-304-6337 / email@example.com
This research study is being done to see how an investigational drug called DKN-01 combined with standard cancer drugs (gemcitabine and cisplatin) works in people with biliary or gallbladder cancer. DKN-01 is an antibody that blocks the function of another protein in the body called dickkopf-1 (Dkk-1). Too much (over expression) of the Dkk-1 protein has been implicated in tumor growth and disease progression and elevated levels may play a role in the growth and spread of biliary, gallbladder, and other cancers. DKN-01 is being studied in multiple investigational research studies including this one to see whether it can slow tumor growth and help patients with different types of cancer.
This study is closed
Gulam Manji, MD, PhD
|Have you been diagnosed with either gallbladder or biliary cancer?
|Have you had a major organ transplant?